Synapse Open Synapse
Biology

Merck KGaA bets on RNAi with $1.3B Silence buyout

BioPharma Dive · · 2 min read

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

Latest from BioPharma Dive